Bahrain Pharmaceuticals and Healthcare Report Q2 2009

Publication Date	May 2009
Publisher	Business Monitor
Product Type	Report
Pages	78
ISBN Number	1748-1775
Product Code	BMI03858

Buy this product or for assistance call +44 20 7060 7474

PDF £250.00$410 | €277

FAX Order above formats by FAX

Summary

In BMI's Q209 Business Environment Rating for the 17 countries of the MEA region, Bahrain improved its position to fourth, from equal sixth. While the country's overall score is negatively impacted by the small population, the low-risk economic and political climates and strong pharmaceutical-specific regulatory framework represent major positives for foreign drugmakers, especially given the preference for patented and branded prescription drugs, a relatively generous reimbursement system and the unchallenging distribution network. The population is also growing relatively quickly, which should help to boost future returns, Overall, we expect total drug market spending to increase from US$73.2mn in 2008 to US$97.6mn by 2013, implying a steady compound annual growth rate (CAGR) of just over 5.9%.

The demand for healthcare services is expected to increase considerably, especially as chronic and longterm diseases have come to represent most of the mortality and morbidity burden. For example, according to a February 2009 TradeArabia article, the number of newborn children with type I (insulin-dependent) diabetes rose almost tripled between 1993 and 2008. Similarly, around 26% of Bahraini population presently suffers from hypertension, while asthma has also emerged as a pressing health concern due to worsening air quality.

On a positive note, in March 2009 the Bahraini health minister announced that the number of patients presenting with sickle cell anaemia and thalassemia fell as a result of the government's pre-marriage screening programmes and improved treatment of sufferers. The long-term health policy instilled by the state not only includes designated hospital units for sickle cell anaemic children, but also plans to finance additional facilities to treat adults. BMI believes that Bahrain's successful strategy for preventing congenital diseases will be attractive to multinational firms involved in genetic sequencing and anaemic disease management.

On an economic front, the news is similarly encouraging. While there are substantial macroeconomic risks in 2009 - but assuming an oil price bounce in the second half of the year - Bahrain should continue to record positive real growth rates. Nevertheless, we have revised down our forecasts for Bahraini growth to 3.5% in 2009 from our previous projection of 4.3%. The changes were made on the premise that the services-oriented economies are more exposed to global consumer demand and liquidity shortages, and will therefore be affected to a larger degree. Against this backdrop, we are forecasting consumer spending growth of 3.0% for 2009 and 2010, rising to 4.0% in 2011-2012 and then 5.0% in 2013. This should also work towards supporting the development of the over-the-counter (OTC) medicines market, from a currently low base of US$3.7mn. OTCs will also be boosted by the recent Gulf Cooperation Council (GCC)-wide proposals to introduce harmonised traditional and alternative medicines legislation, put forward in response to the increase in the use of herbal treatments.

Content

Executive Summary
Bahrain Pharmaceuticals And Healthcare Industry SWOT
Bahrain Political SWOT
Bahrain Economic SWOT
Bahrain Business Environment SWOT
Pharmaceutical Business Environment Ratings
Limits of Potential Returns
Risks to Realisation of Returns
Bahrain - Market Summary
Regulatory Regime
Recent Regulatory Developments
GCC Healthcare Collaboration
Intellectual Property Developments
Pricing and Reimbursement Regime
Regional Price Harmonisation
Free Trade Agreement with the US
Other Free Trade Agreements
Industry Developments
Epidemiology
HIV/AIDS
Healthcare Sector
Primary, Secondary and Tertiary Healthcare
Health Insurance
Strategic Healthcare Goals
Healthcare Sector Investment
Features Of Dilmunia Health Island
Pharmaceutical Sector
Pharmaceutical Retail
Research and Development
International Collaboration
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors - Industry
Key Growth Factors - Macroeconomic
Prescription Market Forecast
Patented Market Forecast
Generics Drug Market Forecast
OTC Market Forecast
Pharmaceutical Trade Forecast
Medical Devices
Other Healthcare Data Forecasts
Key Risks to BMI's Forecast Scenario
Competitive Landscape
Company Monitor
Multinational Companies
Novartis
Johnson & Johnson
Merck & Co
Pfizer
GlaxoSmithKline
GlaxoSmithKline
Indigenous Companies
Bahrain Industrial Pharmaceutical Co (Bidapharm)
Al-Jishi Corporation
Behzad Medical Establishment
Yousuf Mahmood Husain Company
Country Snapshot: Bahrain Demographic Data
Section 1: Population
Section 2: Education and Healthcare
Section 3: Labour Market and Spending Power
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Weighting
Sources
List of Tables
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings for Q209
- Table: Leading Causes Of Death In Bahrain, 2002
- Table: National Health Insurance Scheme Breakdown
- Table: Bahrain - Drug Expenditure Indicators, Historical Data and Forecasts
- Table: Bahrain - Health Expenditure Indicators, Historical Data and Forecasts
- Table: Bahrain - Economic Activity
- Table: Bahrain - Prescription Market Indicators, Historical Data and Forecasts (BHDmn unless otherwise indicated)
- Table: Bahrain - Prescription Drug Market Indicators, Historical Data and Forecasts
- Table: Bahrain - Generics Drug Market Indicators, Historical Data and Forecasts
- Table: Bahrain - OTC Market Indicators, Historical Data and Forecasts (BHDmn unless otherwise stated)
- Table: Bahrain - Pharmaceutical Trade Balance Indicators, Historical Data and Forecasts (US$mn)
- Table: Bahrain - Medical Device Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated)
- Table: Bahrain - Other Health Indicators, Historical Data and Forecasts
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Table: Education
- Table: Vital Statistics, 2005-2030
- Table: Employment Indicators
- Table: Consumer Expenditure, 1999-2004 (US$)
- Table: Average Annual Wages
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components

Delivery Details

PDF:Immediate delivery

Ask a question about this product

Need help finding the right product?

Product features / use

Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted